Terminated PHASE2 INTERVENTIONAL 3-arm NCT05678257

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer

Sponsor: NuCana plc

Conditions Colorectal Adenocarcinoma Colorectal Cancer Colorectal Cancer Metastatic Colorectal Neoplasms Neoplasm, Colorectal

Interventions 5-FU Bevacizumab Fosifloxuridine Nafalbenamide Irinotecan Leucovorin

Updated 13 times since 2023 Last updated: Aug 25, 2025 Started: Apr 18, 2023 Primary completion: Aug 29, 2024 Completion: Aug 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.

Other terminated trials from NuCana plc

More terminations from NuCana plc

Other Colorectal Adenocarcinoma trials with similar outcome

Browse all Colorectal Adenocarcinoma trials

A PHASE2 clinical study on Colorectal Adenocarcinoma and Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by NuCana plc and has accumulated 13 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

13 versions recorded

Oct 2025 — Present [monthly]

Terminated PHASE2
Sep 2025 — Oct 2025 [monthly]

Terminated PHASE2
Oct 2024 — Sep 2025 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 8 earlier versions

May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2024 — May 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Mar 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Jun 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NuCana plc

Data source: NuCana plc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcorcón, Spain , Ancona, Italy , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Besançon, France , Bordeaux, France , Boston, United States , Cardiff, United Kingdom , Cincinnati, United States and 41 more locations